News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

After Adverse Effects, Roche Applied Science and Ipsen Ends Trials of Diabetes Drug Taspoglutide


9/13/2010 7:26:50 AM

New York Times -- The drug maker Roche has stopped giving patients its experimental diabetes treatment taspoglutide in late-stage clinical trials because of a high rate of adverse reactions, a major blow to a drug once expected to have $2 billion-a-year potential.

Read at New York Times
Read at Wall Street Journal
Read at Reuters

comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES